Cohort Study of Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease Initiating Olodaterol or Other Long-acting beta2-agonists
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Olodaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 25 Nov 2019 Planned number of patients changed from 1 to 150000.
- 26 Jun 2018 Planned End Date changed from 31 Mar 2020 to 31 Jul 2020.
- 26 Jun 2018 Planned primary completion date changed from 31 Mar 2020 to 31 Jul 2020.